Rise In Genetic And Chronic Diseases Fueling The Growth Of The Market Due To Advancements In Genetic Testing And Personalized Treatment Needs Is Supporting Development Across The Nucleic Acid Therapeutics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Market Value Of The Nucleic Acid Therapeutics Market Projected To Expand During 2026–2030?

The nucleic acid therapeutics market has seen rapid expansion in recent years. Its value is expected to grow from $6.94 billion in 2025 to $8.01 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.4%. In previous periods, this growth was fueled by factors including the limited availability of nucleic acid therapeutics, a reliance on traditional small molecule therapies, an escalating demand for precision medicine, early regulatory approvals for gene therapies, and expanding academic research focused on gene modulation.

The nucleic acid therapeutics market size is expected to show rapid expansion in the coming years. It is forecast to grow to $14.07 billion in 2030, achieving a compound annual growth rate (CAGR) of 15.1%. The growth anticipated during this period is driven by the development of CRISPR and other gene editing technologies, the expansion of lipid nanoparticle (LNP) delivery systems, the increasing adoption of personalized nucleic acid therapies, growing collaborations between pharmaceutical and biotechnology companies, and rising investment in RNA-based therapeutics. Key trends for the forecast period include the increasing use of antisense oligonucleotides (ASOs) and siRNA therapies, the broadening scope of CRISPR-based and gene editing therapeutics, an increase in targeted therapies for neuromuscular, metabolic, and oncological disorders, augmented investment in non-viral and viral delivery systems, and the emergence of long non-coding RNA (lncRNA) and microRNA (miRNA) therapeutics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp

What Core Drivers Are Transforming The Nucleic Acid Therapeutics Market?

The rising prevalence of genetic and chronic diseases is anticipated to boost the nucleic acid therapeutics market’s growth moving forward. Genetic and chronic diseases describe the connection between inherited genetic elements and the onset, progression, or risk of long-term health issues such as diabetes, cardiovascular diseases, cancer, and autoimmune disorders. The increase in these genetics-related and chronic conditions can largely be attributed to improved diagnostic technologies that enable more accurate and earlier identification. Nucleic acid therapeutics are valuable for addressing genetic and chronic diseases because they can target and modify the core genetic causes of these conditions by regulating, repairing, or silencing specific genes, thus offering precise and personalized treatment options. For instance, in October 2024, data from the Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, showed that 11,148 cystic fibrosis patients were registered in 2022, a number that rose to 11,318 in 2023, indicating a 1.5% year-over-year increase in patient registrations. Therefore, the growing number of genetic and chronic diseases is a key driver for the expansion of the nucleic acid therapeutics market.

How Is Segment Classification Applied In The Nucleic Acid Therapeutics Market?

The nucleic acid therapeutics market covered in this report is segmented –

1) By Therapy Type: Antisense Oligonucleotides (ASOs), Small Interfering RNA (siRNA), Gene Therapies, Aptamers, Other Therapy Types

2) By Therapeutic Area: Neuromuscular Disorder, Metabolic Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Oncological Disorders, Other Therapeutic Areas

3) By Route Of Administration: Intravenous, Subcutaneous, Other Route Of Administrations

4) By Delivery Method: Viral Vector-Based Delivery Systems, Non-Viral Delivery Systems

5) By End-Use: Pharmaceutical Companies, Government And Academic Research Institutes, Biotech Companies

Subsegments:

1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs, 2’-O-Methyl ASOs, Locked Nucleic Acid (LNA) ASOs, Gapmer ASOs, Morpholino ASOs

2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA, GalNAc-Conjugated siRNA, Chemically Modified siRNA, Naked siRNA

3) By Gene Therapies: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, CRISPR-Based Gene Therapy, Zinc Finger Nucleases (ZFNs), TALENs

4) By Aptamers: Ribonucleic Acid (RNA) Aptamers, Deoxyribonucleic Acid (DNA) Aptamers, Spiegelmers, Pegylated Aptamers

5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics, Long Non-Coding RNA (lncRNA) Therapeutics, Ribonucleic Acid (RNA) Editing Therapies, Ribozymes

What Trends Are Affecting The Nucleic Acid Therapeutics Market Dynamics?

Major companies within the nucleic acid therapeutics market are concentrating on developing innovative products, such as antisense oligonucleotide therapy, to target and silence specific disease-causing genes, thereby offering precise treatment options for genetic disorders and rare diseases. This type of therapy is a precision treatment utilizing short, synthetic strands of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to block or modify the expression of particular genes involved in disease. For instance, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology company, received U.S. Food and Drug Administration (FDA) approval for TRYNGOLZ (olezarsen) as an adjunct therapy to diet for lowering triglyceride levels in adults diagnosed with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe hypertriglyceridemia (sHTG) and a high risk of acute pancreatitis (AP). This approval represents the first FDA-approved treatment capable of delivering significant and sustained triglyceride reduction in this patient population, alongside a clinically meaningful decrease in AP incidence when combined with a low-fat diet. The therapy is designed for convenient self-administration via a once-monthly auto-injector.

Which Organizations Are Operating Within The Nucleic Acid Therapeutics Market?

Major companies operating in the nucleic acid therapeutics market are Pfizer Inc., Novartis AG, Moderna Inc., BioNTech SE, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc.

Access The Complete Nucleic Acid Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/nucleic-acid-therapeutics-global-market-report

Which Region Has The Strongest Presence In The Nucleic Acid Therapeutics Market?

North America was the largest region in the nucleic acid therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nucleic acid therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Nucleic Acid Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27368&type=smp

Browse Through More Reports Similar to the Global Nucleic Acid Therapeutics Market 2026, By The Business Research Company

Sandwich Panels Market Report 2026

https://www.thebusinessresearchcompany.com/report/sandwich-panels-global-market-report

Structural Insulated Panels Market 2026

https://www.thebusinessresearchcompany.com/report/structural-insulated-panels-market

Metal Structural Insulation Panels Market Report 2026

https://www.thebusinessresearchcompany.com/report/metal-structural-insulation-panels-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795